Stocks News

LAST PRICE
34.0700
TODAY'S CHANGE (%)
Trending Down-0.8000 (-2.2942%)

Bid / Lots
33.3600/ 1
Ask / Lots
34.7900/ 1
Open / Previous Close
34.6900 / 34.8700
Day Range
Low 34.0100
High 35.0300
52 Week Range
Low 23.0450
High 35.5600
Volume
377,694
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024, from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: SUPN
  
  Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
  
  Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms
Oct 21, 2024
- Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results, from 4:25PM ET on Monday Oct 21, 2024 by Dow Jones
  4:25PM ET on Monday Oct 21, 2024 by Dow Jones
  Companies Mentioned: SUPN
  
  Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
  
  ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2024 after the market closes on Monday, November 4, 2024.
Oct 17, 2024
- Supernus Pharmaceuticals Reports 'Promising' Data in Trial of Anti-Depression Drug Candidate, from 6:01PM ET on Thursday Oct 17, 2024 by MT Newswires
  6:01PM ET on Thursday Oct 17, 2024 by MT Newswires
  Companies Mentioned: SUPN
  06:01 PM EDT, 10/17/2024 (MT Newswires) -- Supernus Pharmaceuticals (SUPN) said late Thursday the phase 2a open-label study of SPN-820 in adults with major depressive disorder yielded "promising" data. The company said the study evaluated the safety...
- Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder, from 4:05PM ET on Thursday Oct 17, 2024 by Dow Jones
  4:05PM ET on Thursday Oct 17, 2024 by Dow Jones
  Companies Mentioned: SUPN
  
  Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
  
  Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms
Oct 10, 2024
- Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder, from 5:12PM ET on Thursday Oct 10, 2024 by Dow Jones
  5:12PM ET on Thursday Oct 10, 2024 by Dow Jones
  Companies Mentioned: SUPN
  
  Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
  
  ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder.

Today
- Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products, from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: PAHC
- Press Release: Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products, from 4 hours ago by Dow Jones
  4 hours ago by Dow Jones
  Companies Mentioned: ZTS, PAHC
- Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan, from 13 hours ago by Dow Jones
  13 hours ago by Dow Jones
  Companies Mentioned: EGRX
Oct 23, 2024
- Press Release: Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results, from 4:42PM ET on Wednesday Oct 23, 2024 by Dow Jones
  4:42PM ET on Wednesday Oct 23, 2024 by Dow Jones
  Companies Mentioned: PAHC
- Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results, from 4:00PM ET on Wednesday Oct 23, 2024 by Dow Jones
  4:00PM ET on Wednesday Oct 23, 2024 by Dow Jones
  Companies Mentioned: PAHC
Oct 22, 2024
- INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Eagle Pharmaceuticals, Inc. On Behalf of Shareholders, from 7:31PM ET on Tuesday Oct 22, 2024 by Dow Jones
  7:31PM ET on Tuesday Oct 22, 2024 by Dow Jones
  Companies Mentioned: EGRX
Oct 14, 2024
- Snowflake, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information, from 6:13PM ET on Monday Oct 14, 2024 by Dow Jones
  6:13PM ET on Monday Oct 14, 2024 by Dow Jones
  Companies Mentioned: SNOW, BRBS, AMPL, EGRX
Oct 8, 2024
- BofA Securities Adjusts Price Target on Phibro Animal Health to $21 From $15, from 10:27AM ET on Tuesday Oct 08, 2024 by MT Newswires
  10:27AM ET on Tuesday Oct 08, 2024 by MT Newswires
  Companies Mentioned: PAHC
Oct 2, 2024
- Sector Update: Health Care Stocks Decline Late Afternoon, from 3:52PM ET on Wednesday Oct 02, 2024 by MT Newswires
  3:52PM ET on Wednesday Oct 02, 2024 by MT Newswires
  Companies Mentioned: HUM, LLY, ESTA, EGRX
- Top Midday Decliners, from 2:31PM ET on Wednesday Oct 02, 2024 by MT Newswires
  2:31PM ET on Wednesday Oct 02, 2024 by MT Newswires
  Companies Mentioned: HUM, STTK, EGRX

Supernus Pharmaceuticals Inc
NASDAQ:SUPNUnited States

Search Criteria

Today

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024, from 4 hours ago by Dow Jones

Oct 21, 2024

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results, from 4:25PM ET on Monday Oct 21, 2024 by Dow Jones

Oct 17, 2024

Supernus Pharmaceuticals Reports 'Promising' Data in Trial of Anti-Depression Drug Candidate, from 6:01PM ET on Thursday Oct 17, 2024 by MT Newswires

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder, from 4:05PM ET on Thursday Oct 17, 2024 by Dow Jones

Oct 10, 2024

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder, from 5:12PM ET on Thursday Oct 10, 2024 by Dow Jones

Peers Headlines

Today

Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products, from 4 hours ago by Dow Jones

Press Release: Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products, from 4 hours ago by Dow Jones

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan, from 13 hours ago by Dow Jones

Oct 23, 2024

Press Release: Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results, from 4:42PM ET on Wednesday Oct 23, 2024 by Dow Jones

Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results, from 4:00PM ET on Wednesday Oct 23, 2024 by Dow Jones

Oct 22, 2024

INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Eagle Pharmaceuticals, Inc. On Behalf of Shareholders, from 7:31PM ET on Tuesday Oct 22, 2024 by Dow Jones

Oct 14, 2024

Snowflake, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information, from 6:13PM ET on Monday Oct 14, 2024 by Dow Jones

Oct 8, 2024

BofA Securities Adjusts Price Target on Phibro Animal Health to $21 From $15, from 10:27AM ET on Tuesday Oct 08, 2024 by MT Newswires

Oct 2, 2024

Sector Update: Health Care Stocks Decline Late Afternoon, from 3:52PM ET on Wednesday Oct 02, 2024 by MT Newswires

Top Midday Decliners, from 2:31PM ET on Wednesday Oct 02, 2024 by MT Newswires